New Hampshire Code of Administrative Rules
Nat - Naturopathic Board of Examiners
Chapter Nat 400 - CONTINUED STATUS
Part Nat 406 - FORMULARY
Section Nat 406.01 - Formulary

Universal Citation: NH Admin Rules Nat 406.01

Current through Register No. 12, March 21, 2024

Pursuant to RSA 328-E:16, III, the formulary for licensees shall be as follows:

(a) Amino acids and peptides, including but not limited to:

(1) Acetyl Carnitine;

(2) EDTA;

(3) GABA;

(4) Glutathione;

(5) Levocarnitine;

6) Succinic Acid (DMSA); and

(7) Tryptophan;

(b) Animal preparations and their derivatives, including but not limited to:

(1) Adrenal;

(2) Thymus;

(3) Thyroid;

(4) Fish oils, including derived mega-3 fatty acids such as Ethyl eicosapentaenoic acid, docosahexaenoic acid, and omega-3 carboxylic acids;

(5) Hyaluronic acid; and

(6) Bile acids, including deoxycholic acid;

(c) The following anti-gout agents:

(1) Allopurinol;

(2) Colchicine; and

(3) Probenecid;

(d) H1 and H2 antihistamine-class agents;

(e) The following anti-leukotriene agents:

(1) Montelukast; and

(2) Zafirlukast;

(f) The following anti-hyperglycemic agents:

(1) The alpha glucosidase inhibitor Acarbose;

(2) The biguanide Metformin;

(3) Sulfonylurea-class agents;

(4) Thiazolidinedione-class agents (TZDs);

(5) Sodium-glucose transport protein 2 (SGLT-2) inhibitors;

(6) Dipeptidyl peptidase 4 (DPP-4) inhibitors;

(7) Glucagon-like peptide-1 (GLP-1) receptor agonists; and

(8) Synthetic and human insulin;

(g) The following anti-infective agents:

(1) The following antibacterial agents:
a. Aminoglycosides, including but not limited to:
1. Gentamicin;

2. Kanamycin sulfate; and

3. Tobramycin;

b. The following beta-lactam antibiotics:
1. Cephalosporins, including but not limited to:
(i) Cefaclor;

(ii) Cefadroxil;

(iii) Cefdinir;

(iv) Ceditoren;

(v) Cefibuten;

(vi) Cefixime;

(vii) Cefonicid sodium;

(viii) Cepodoxime proxetil;

(ix) Cefprozil;

(x) Ceftibuten;

(xi) Cefuroxime;

(xii) Cephalexin; and

(xiii) Cephradine; and

2. Penicillins, including but not limited to:
(i) Amoxicillin and clavulanate;

(ii) Amoxicillin;

(iii) Ampicillin and sulbactam;

(iv) Ampicillin;

(v) Bacampicillin;

(vi) Cloxacillin;

(vii) Dicloxacillin;

(viii) Oxacillin; and

(ix) Penicillin;

c. Macrolides and ketolides, including but not limited to:
1. Azithromycin;

2. Clarithromycin;

3. Dirithromycin;

4. Erythromycins;

5. Telithromycin; and

6. Troleandomycin;

d. Quinolones, including but not limited to:
1. Ciprofloxacin;

2. Levofloxacin; and

3. Ofloxacin;

e. The following sulfonamides:
1. Sulfonamide;

2. Sofamethoxazole;

2. Trimethoprim; and

3. Dapsone;

f. Tetracyclines, including but not limited to:
1. Demeclocycline hydrochloride;

2. Doxycycline;

3. Minocycline;

4. Oxytetracycline; and

5. Tetracycline;

g. The following miscellaneous antibacterials:
1. Bacitracin;

2. Clindamycin;

3. Colistimethate;

4. Lincomycin;

5. Novobiocin;

6. Polymyxin B Sulfate;

7. Spectinomycin;

8. Vancomycin;

9. Daptomycin; and

(2) Antifungals, such as:
a. Polyene;

b. Amphotericin B;

c. Nystatin;

d. Fluconazole;

e. Ketoconazole;

f. Clotrimazole;

g. Terbinafine; and

h. Itraconazole;

(3) The following anti-virals:
a. Valcyclovir;

b. Acyclovir;

c. Famciclovir; and

d. Oseltamivir;

(4) Anti-helmetics, such as:
a. Mebendazole;

b. Thiabendazole;

c. Nitazoxanide;

d. Albendazole;

e. Ivermectin; and

f. Praziquantel;

(5) The following antitubercular and antimycobacterial agents:
a. Aminosalicylic acid;

b. Cycloserine;

c. Pyrazinamidel

d. Rifabutin; and

e. Rifampin;

(6) The following antiprotozoal and antiparasitic agents:
a. The halogenated 8-hydroxyquinoline iodoquinol;

b. The following nitroimidazoles:
1. Metronidazole; and

2. Tinidazole;

c. The following quinolines:
1. Chloroquine;

2. Hydroxychloroquine;

3. Mefloquine; and

4. Quinine sulfate; and

d. The hydroxynaphthoquinone atovaquone; and

(7) The following miscellaneous anti-infective agents:
a. Mupirocin;

b. Permethrin; and

c. Pyrethrins;

(h) The following anti-thyroid agent thionamides (thioureylenes) :

(1) Methimazole; and

(2) Propylthiouracil;

(i) The following autonomic agents:

(1) The following cholinergic agents:
a. The following antimuscarinic agents:
1. Atropine;

2. Atropine sulfate;

3. Belladonna;

4. Flavoxate;

5. Homatropine hydrobromide;

6. Hyoscyamine;

7. Methscopolamine; and

8. Scopolamine;

b. The muscarinic receptor agonist pilocarpine;

c. Nicotinic receptor agonists:
1. Nicotine; and

2. Varenicline; and

d. The following acetylcholinesterase inhibitors:
1. Donepezil;

2. Galantamine; and

3. Rivastigmine;

(2) The following ergot derivatives:
a. Ergonovine maleate; and

b. Methergine;

(3) The following sympathomimetics:
a. Ephedrine;

b. Epinephrine, including autoinject forms;

c. Pseudoephedrine;

d. Midodrine;

e. Clonidine;

f. Guanfacine;

g. Albuterol;

h. Formoterol; and

i. Salmetrol;

(4) The following sympatholytic agents:
a. The following alpha adrenergic blocking agents:
1. Yohimbine; and

2. Tamulosin; and

b. Beta adrenergic blocking agents, including but not limited to:
1. Atenolol;

2. Bisoprolol;

3. Metoprolol;

4. Propranolol; and

5. Timolol; and

(5) The following agents for ADHD/Narcolepsy treatment:
a. Methylphenidate;

b. Dexmethylphenidate;

c. Amphetamine/dextroamphetamine;

d. Dextroamphetamine;

e. Lisdexamfetamine;

f. Atomoxetine; and

g. Modafinil;

(j) The following biologicals:

(1) The following biological response modifiers:
a. Candida and tricophyton extracts; and

b. Rho(D) immune globulins;

(2) The following skin test antigens:
a. Purified protein derivative tuberculin tests;

b. Candida albicans skin test antigen; and

c. Coccidioides immitis spherule derived skin test antigen;

(3) Blood typing serum;

(4) Blood and tissue derived products;

(5) Enzymes, including but not limited to:
a. Amylase;

b. Collagenase;

c. Desoxyribonuclease;

d. Fribinolysin;

e. Hyaluronidase;

f. Lipase;

g. Pancrelipase; and

h. Papain;

(6) Electrolytes and fluid replacements, including but not limited to:
a. Saline solutions;

b. Sterile water;

c. D5W;

d. Lactated ringers solution; and

e. Sodium bicarbonate;

(7) Hormones as described in Nat 406.01(p);

(8) Immune globulins;

(9) Prostaglandins and prostaglandin analogs, including but not limited to:
a. Alprostadil;

b. Bimatoprost;

c. Dinoprostone;

d. Iloprost; and

e. Misoprostal; and

(10) Botolinum toxin derivatives:
a. Onabotilinumtoxin A;

b. Abobotulinumtoxin A; and

c. Incobotilinumtoxin A;

(k) Botanical preparations, with the following exceptions::

(1) Legend or controlled Digitalis species derivatives;

(2) Legend or controlled Coca species derivatives;

(3) Legend or controlled Vinca species derivatives;

(4) Legend or controlled Taxus species derivatives;

(5) Legend or controlled Rauwolfia species derivatives; and

(6) Derivatives of Papaver somniferum unless otherwise specified;

(l) The following cardiovascular agents:

(1) The following antilipemics:
a. HMG CoA reductase inhibitors, such as:
1. Atorvastatin;

2. Fluvastatin;

3. Lovastatin;

4. Pravastatin; and

5. Simvastatin;

b. Cholestyramine; and

c. Colesevelam;

(2) The following anti-angina, piperazine derivative, metabolism modifiers, or p-FOX inhibitors;
a. Ranolazine; and

b. Trimetazidine;

(3) The following anti-angina nitrates:
a. Nitroglycerin;

b. Isosorbide dinatrate; and

c. Isosobide mononitrate;

(4) Dihydropyridine-class calcium channel blockers;

(5) The following non-dihydropyridine calcium channel blockers:
a. Diltiazem; and

b. Verapamil;

(6) Angotensin converting enzyme inhibitors;

(7) Angiotensin II receptor blockers;

(8) The following diuretics:
a. Chlorthalidone;

b. Hydrochlorothiazide;

c. Epleronone; and

d. Spironolactone; and

(9) The following anti-coagulant agents:
a. Heparin for in-office use;

b. Heparin flushes;

c. Warfarin;

d. Apixaban; and

e. Rivaroxaban;

(m) The following central nervous system agents:

(1) The following anticonvulsant and antipeptic agents:
a. Gabapentin;

b. Tiagabine;

c. Pregabalin;

d. Carbamazepine;

e. Oxcarbazepine;

f. Lamotrigine; and

g. Toiramate;

(2) The following antispasmodics:
a. Baclofen;

b. Cyclobenzaprine;

c. Methocarbamol; and

d. Tizanidine;

(3) The following anxiolytics, sedatives and hypnotics:
1. The following benzodiazepines;
a. Alprozolam;

b. Chlordiazepoxide;

c. Clobazam;

d. Clonazepam;

e. Diazepam;

f. Lorazepam; and

g. Temazapam;

2. The following non-benzodiazepine sedative-hypnotic agents:
a. The imidazopyridine agent Zolpidem;

b. The cyclopyrrolone agent Eszopiclone;

c. Suvorexant; and

d. Ramelteon;

3. The anti-manic agent Lithium; and

4. The anxiolytic Buspirone; and

(4) Antidepressants for FDA approved age groups:
a. The following selective serotonin reuptake inhibitors (SSRIs):
1. Citalopram;

2. Escitalopram;

3. Fluoxetine;

4. Paroxetine; and

5. Sertraline;

b. Serotonin-norepinephirene reuptake inhibitors (SNRIs):
1. Duloxetine;

2. Desvenlafaxine; and

3. Venlafaxine; and

c. The following tricyclic antidepressants (TCAs):
1. Amitriptyline;

2. Doxepin;

3. Imipramine;

4. Nortriptyline; and

5. Clomipramine;

(n) The following erectile dysfunction agents:

(1) Tadalafil; and

(2) Sildenafil;

(o) Homeopathic preparations and their derivatives including both sterile injectable and non-injectable dosage forms;

(p) Hormones such as:

(1) Adrenal hormones, such as:
a. Aldosterone;

b. DHEA;

c. Epinephrine;

d. Pregnenalone; and

e. Synthetic glucocorticoids such as:
1. Betamethasone;

2. Cortisone acetate;

3. Dexamethasone;

4. Triamcinolone and Triamcinolone acetonide;

5. Methylprednisolone and Prednisolone;

6. Prednisone; and

7. Hydrocortisone;

(2) Selective estrogen-receptor modulators (SERMs), and anti-estrogens or estrogen antagonists, such as:
1. Clomiphene;

2. Tamoxifen;

3. Toremifene; and

4. Raloxifene; and

(3) Gonadal hormones, such as:
a. Conjugated estrogens;

b. Estrogen;

c. Estradiol;

d. Estriol;

e. Estrone;

f. Estropipate;

g. Ethinyl estradiol;

h. HCG;

i. Progesterone;

j. Quinestrol; and

k. Testosterone;

(4) Thyroid hormones, such as:
a. Levothyroxine;

b. Liothyronine;

c. Natural dessicated thyroid hormones; and

d. Calcium;

(5) Pituitary hormones, such as:
a. ACTH;

b. Growth hormones; and

c. Oxytocin; and

(6) Hormonal modifiers, such as:
a. Dutasteride;

b. Finasteride; and

c. Anastrazole;

(q) Antitussives, such as:

(1) Codeine for cough;

(2) Guafenesin; and

(3) Benzonatate;

(r) Local anesthetics, including both injectable and non-injectable dosage form such as:

(1) Amino esters for in-office use:
a. Procaine;

b. Chloroprocaine;

c. Tetracaine; and

d. Benzocaine;

(2) Amino amides, for in-office use:
a. Lidocaine;

b. Mepivocaine;

c. Bupivacaine;

d. Levobupacaine;

e. Etidocaine; and

f. Prilocaine;

(3) The following other topical anesthetics:
a. The ketone Dyclonine, for in-office use;

b. The ether Pramoxine;

c. The skin refrigerant ethyl chloride, also known as chloroethane; and

d. Topical lidocaine; and

(4) The methyl group donor betaine;

(s) Anti-psoriatic agents for topical use only:

(1) Dithranol (anthralin);

(2) Calcipotriene;

(3) Fluocinonide; and

(4) Tacrolimus;

(t) Minerals, trace minerals, and their derivatives, such as super saturated potassium iodine (SSKI);

(u) The following miscellaneous agents:

(1) Acamprosate;

(2) Acetazolamide;

(3) Bee venom;

(4) Crofelemer;

(5) Cromolyn sodium;

(6) DMPS;

(7) DMSO;

(8) Ethyl Chloride spray;

(9) Fluro-ethyl spray;

(10) Fluro-methane spray;

(11) Hydrogen peroxide;

(12) Hydrochloric acid;

(13) Methylsulfonylmethane;

(14) Ondansetron;

(15) Oxygen;

(16) Ozone;

(17) Poly-L-lactic acid and derivatives;

(18) Salicylates, propionic acid, and acetic acid derivatives such as:
a. Mesalamine;

b. Topical salicyclic acid preparations;

c. Indomethacin;

d. Ibuprofen;

e. Naproxen;

f. Ketorolac; and

g. Diclofenac; and

(19) Urea;

(v) In-office medical equipment, medical devices, and therapeutic devices such as:

(1) Needles;

(2) Syringes;

(3) IV Tubing;

(4) Filters;

(5) The following barrier contraceptives:
a. Cervical caps; and

b. Diaphragms, excluding intrauterine devices;

(6) Nebulizers, inhalers, spacers, actuators, and mouthpieces for medication delivery;

(7) CPAP machies and medical devices for the treatment and prevention of sleep apnea; and

(8) Auditory devices.

(w) Agents needed to carry out diagnostic tests or physiological function tests such as:

(1) Mannitol;

(2) Methacholine;

(3) Dexamethasone;

(4) Dyes and contrasts such as:
a. Imaging contrasts;

b. Methylene blue; and

c. Triple dye;

(x) Vaccinations, provided they are for use and not prescription, including but not limited to:

(1) BCG;

(2) Cholera;

(3) Diphtheria;

(4) DPT;

(5) Haemophilus b Conjugate;

(6) Hepatitus A Virus;

(7) Hepatitus B;

(8) Influenza Virus;

(9) Japanese Encaphalitis Virus;

(10) Measles Virus;

(11) Mumps virus;

(12) Pertussis;

(13) Plague;

(14) Pneumococcal;

(15) Polio virus - inactivated;

(16) Poliovirus - live oral;

(17) Rabies;

(18) Rubella;

(19) Smallpox;

(20) Tetanus IG;

(21) Tetanus Toxoid;

(22) Typhoid;

(23) Varicella;

(24) Yellow fever; and

(25) Covid-19.

(y) All forms of prescription and non-prescription vitamin preparations and their derivatives, except for Isotretinoin; and

(z) Anti-addictive agents:

(1) Disulfiram;

(2) Naltrexone; and

(3) Naloxone.

#8679, eff 7-11-06; ss by #9656, eff 2-13-10

Disclaimer: These regulations may not be the most recent version. New Hampshire may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.